Capstan Medical
Series C in 2024
Capstan Medical specializes in developing minimally invasive technologies for treating heart valve disorders. Their core product is a catheter-based system designed to revolutionize the treatment of structural heart disease, providing a less invasive alternative to traditional open heart surgery. This technology ensures precise and reliable placement of heart valve implants, reducing recovery time and minimizing the risk of complications for patients.
XII Medical
Series B in 2024
XII Medical is a medical device developer focused on addressing obstructive sleep apnea through innovative technology. The company specializes in creating a minimally invasive outpatient solution that utilizes an implantable neurostimulation device. This device functions by preventing the muscles in the throat from relaxing during sleep, thereby avoiding airway blockage. By enhancing oropharyngeal airflow, XII Medical aims to provide patients with a proactive approach to managing their sleep apnea, improving their overall quality of life.
Endogenex
Series C in 2024
Endogenex develops a novel endoscopic procedure using pulsed electric fields to regenerate the duodenal mucosa, aiming to improve glycemic control in patients with Type 2 Diabetes.
Amber Therapeutics
Series A in 2024
Amber Therapeutics specializes in developing advanced bioelectronic therapies that can sense and adapt, aiming to enhance clinical outcomes for patients with functional disorders of the peripheral nervous system.
Capstan Medical
Series B in 2023
Capstan Medical specializes in developing minimally invasive technologies for treating heart valve disorders. Their core product is a catheter-based system designed to revolutionize the treatment of structural heart disease, providing a less invasive alternative to traditional open heart surgery. This technology ensures precise and reliable placement of heart valve implants, reducing recovery time and minimizing the risk of complications for patients.
Surge Therapeutics
Series B in 2023
SURGE Therapeutics is a biotechnology company focused on enhancing cancer treatment outcomes through innovative immunotherapy solutions. It has developed a proprietary injectable biodegradable hydrogel designed to deliver cancer therapeutics in a prolonged and localized manner. This technology enables targeted release of immunotherapy agents at the surgical site following tumor resection, allowing for more effective treatment administration. By optimizing the timing and location of drug delivery, SURGE Therapeutics aims to improve patient survival rates and minimize systemic side effects, representing a significant advancement in the field of cancer care.
Flywheel.io
Series D in 2023
Flywheel.io is a cloud-based data management platform tailored for biomedical research and collaboration. Founded in 2012 and headquartered in Minneapolis, Minnesota, the company provides a suite of tools designed to enhance the workflow of scientists and researchers. Its platform supports medical imaging, scientific computation, and content management, enabling users to capture, manage, and analyze research data efficiently. By utilizing cloud scalability and automation, Flywheel facilitates collaborative research, machine learning applications, and multicenter studies, which help organizations streamline their research processes. The platform, featuring a modern web interface and extensible compute engine, aims to eliminate bottlenecks in innovation, allowing researchers to focus on scientific discovery rather than IT challenges.
Dasera, Inc. is a data security company based in Sunnyvale, California, that specializes in Data Security Posture Management (DSPM). Founded in 2019, Dasera has developed a query analysis engine designed to enhance data security by automatically identifying, flagging, and rewriting unsafe queries within data warehouses. This innovative platform not only prevents data breaches by monitoring query behavior but also helps organizations manage risks associated with their data lifecycle, from creation to deletion. By automating security and governance controls across structured and unstructured data in various environments, Dasera aims to ensure compliance with evolving data privacy regulations while fostering trust between consumers and companies through the safe use of sensitive data.
Founded in 2016, MedCrypt specializes in cybersecurity software for medical devices. Its solutions ensure data security and protect against unauthorized access across a wide range of devices, from pacemakers to surgical robots.
Founded in 2009, Neocis specializes in robotic guidance systems for dental implant procedures. Its flagship product, Yomi, is a precision instrument that assists surgeons in placing dental implants using advanced robotics and planning software.
Surge Therapeutics
Series A in 2022
SURGE Therapeutics is a biotechnology company focused on enhancing cancer treatment outcomes through innovative immunotherapy solutions. It has developed a proprietary injectable biodegradable hydrogel designed to deliver cancer therapeutics in a prolonged and localized manner. This technology enables targeted release of immunotherapy agents at the surgical site following tumor resection, allowing for more effective treatment administration. By optimizing the timing and location of drug delivery, SURGE Therapeutics aims to improve patient survival rates and minimize systemic side effects, representing a significant advancement in the field of cancer care.
Optellum Ltd is a UK-based company founded in 2015 that specializes in artificial intelligence clinical decision support software specifically for lung cancer diagnosis and treatment. The company has developed an imaging biomarker aimed at enhancing the early detection of lung cancer, the most prevalent and deadly form of cancer globally. Optellum's innovative platform leverages machine learning to analyze vast patient datasets, enabling personalized diagnosis and therapy management for patients at high risk of developing lung cancer. The software not only identifies at-risk patients but also facilitates optimal therapy by automating the analysis of radiology reports, thereby improving clinical decision-making. The founding team consists of experts in medical imaging software and AI, with experience in successfully bringing innovations to market. Optellum is supported by a distinguished Advisory Board of clinicians and deep learning specialists, and is actively expanding its product development team to further its mission in cancer care.
Flywheel.io
Series C in 2021
Flywheel.io is a cloud-based data management platform tailored for biomedical research and collaboration. Founded in 2012 and headquartered in Minneapolis, Minnesota, the company provides a suite of tools designed to enhance the workflow of scientists and researchers. Its platform supports medical imaging, scientific computation, and content management, enabling users to capture, manage, and analyze research data efficiently. By utilizing cloud scalability and automation, Flywheel facilitates collaborative research, machine learning applications, and multicenter studies, which help organizations streamline their research processes. The platform, featuring a modern web interface and extensible compute engine, aims to eliminate bottlenecks in innovation, allowing researchers to focus on scientific discovery rather than IT challenges.
Endogenex
Venture Round in 2021
Endogenex develops a novel endoscopic procedure using pulsed electric fields to regenerate the duodenal mucosa, aiming to improve glycemic control in patients with Type 2 Diabetes.
KelaHealth
Series A in 2020
KelaHealth develops clinical decision support software for surgical care. Its Surgical Intelligence Platform uses patient data to generate predictive insights about individual risk of complications, offers recommended interventions at key decision points, and tracks long-term outcomes to improve care quality. The platform helps standardize surgeon practice, support quality and regulatory compliance, and optimize clinical operations for physicians and hospital administrators, creating a learning ecosystem that continuously enhances surgical outcomes. The company was founded in 2016 and is based in San Francisco, California.
KelaHealth
Seed Round in 2020
KelaHealth develops clinical decision support software for surgical care. Its Surgical Intelligence Platform uses patient data to generate predictive insights about individual risk of complications, offers recommended interventions at key decision points, and tracks long-term outcomes to improve care quality. The platform helps standardize surgeon practice, support quality and regulatory compliance, and optimize clinical operations for physicians and hospital administrators, creating a learning ecosystem that continuously enhances surgical outcomes. The company was founded in 2016 and is based in San Francisco, California.